A Prescription for Profiting on Drug Stocks

When this Barron's article was first published most of the large drug stocks (like most other sectors at that time) were selling at higher prices.

Still, the recent market sell off has created a slightly larger margin of safety on some of the larger drug stock.

Some are doing a better job than others moving beyond traditional patented pharmaceuticals and developing franchises around consumer-products, generics, and vaccines.

In this Barron's article published in early July, industry analyst Tim Anderson (Sanford Bernstein) made projections out to 2015 and 2020 for nine U.S. and European drug companies. Not many analyst project so far out into the future.

His conclusion?

GlaxoSmithKline, Novartis, Pfizer, Merck, Sanofi, and Roche are best positioned long-term.

The Barron's article has a table with a more detailed look at current and projected future price to earnings ratios (among other things) but keep in mind most of the stocks are now selling roughly 10-15% lower so appropriate adjustments need to be made.

Over the long run, these businesses have generally produced above average return on capital yet some difficult to answer questions remain:

Can the pipelines of these businesses be replenished at a high return on capital going forward as older drugs come off patent?

Will the consumer-products, generics, and vaccines businesses eventually add some predictability and robustness to these franchises?

Those questions will not be answered anytime soon so I think a larger margin of safety for most of these companies is warranted.

The valuations seem to mostly reflect the patent cliff and other concerns. Since these businesses are often at the mercy of headlines I prefer to buy the best of these when the headlines are at their worst. Ultimately, I still think the diversified platform owned by Johnson & Johnson (JNJ) (even with its well-publicized recent missteps) is worth the valuation premium.

The recent market sell off did not hit large pharmaceuticals nearly as much as some other sectors.

Still, the patent headwinds, weak R&D productivity, and the market sell off has created a chance to buy shares in large drug companies at what seems a decent discount to intrinsic value.

Even though I think better capital appreciation opportunities exist elsewhere, many of these businesses produce above average dividend yields that can easily be covered with free cash flow.

Yet, for most of these above average capital appreciation is only there if bought at a bigger discount than what is now available.

Adam

Long JNJ, GSK, and SNY
---
This site does not provide investing recommendations as that comes down to individual circumstances. Instead, it is for generalized informational and educational use and the opinions found here should not be treated as specific individualized investment advice. Visitors should always do their own research and consult, as needed, with a financial adviser that's familiar with the individual circumstances before making any investment decisions.
Share on :
A Prescription for Profiting on Drug Stocks
A Prescription for Profiting on Drug Stocks
Reviewed by malaria
Published :
Rating : 4.5